Research brings personalized medicine to treat leukemia one step closer

November 12, 2018

Scientists at the University of Birmingham have revealed the roles that different types of gene mutations play in causing blood cancers in a study that was the culmination of a decade's research.

The findings of the team, led by Professor Constanze Bonifer and Professor Peter Cockerill of the University of Birmingham's Institute of Cancer and Genomic Studies, mean doctors are now one step closer to being able to provide tailored and targeted treatment specific to individual patients - increasing their chances of survival.

The team, funded by blood cancer research charity Bloodwise, has spent the last 10 years carrying out a painstaking global analysis of the cells of patients diagnosed with acute myeloid leukaemia (AML), the results of which are published today (November 12th) in Nature Genetics (i).

AML is an aggressive cancer of the white blood cells, called myeloid cells, which normally function to fight bacterial infections and eliminate parasites from the body.

By picking apart the mutated cells in AML patients and gathering big data on each of them, the researchers were able to study the basic building blocks that control the production of these abnormal cells.

This step-by-step process, carried out in collaboration with Professor Mike Griffiths and his team at the West Midlands Regional Genetics Laboratory at Birmingham Women's and Children's NHS Foundation Trust, identified the main trigger points where critical mutations feed through to other genes that control the cells' identity and behaviour.

Lead author Professor Constanze Bonifer said: "In acute myeloid leukaemia, genes are targeted by mutations that encode either master regulators controlling cell identity or factors transmitting signals through the cell, therefore the normal process of turning genes on or off is defunct.

"Our research found that, when this happens, the cells step sideways from their normal developmental programme and speed out of control.

"Crucially, AML cells from patients with the same types of mutations always take the same route when they head off in the wrong direction. "Our analyses of each of the pathways that the cells took when developing into cancer identified key points in the cell that could be used in the future to target and develop new drugs to treat each type of AML in a different way."

Co-lead author Professor Peter Cockerill said: "Doctors in Birmingham are already testing AML patients for the many different mutations that cause AML. However, now they know which genes are the most important for each type of AML.

"This means that personalised medicine will one day become a reality for blood cell cancers, which will see a different drug being given to treat each form of AML, creating personalised treatment for each cancer patient depending on the mutation that has caused their disease."

Dr Alasdair Rankin, Director of Research at Bloodwise, said: "Although a handful of targeted drugs have recently become available for people with acute myeloid leukaemia, they only help a small number of people.

"We need to be smarter about matching the right treatment to the right person if we want to boost survival rates for AML, especially if there are already drugs out there that can help. "These landmark research findings will act as a blueprint for how to tackle this, and could even help with the delivery of personalised medicine in mainstream healthcare in the future."

This study comes after research, by the same team at the University of Birmingham in collaboration with Professor Olaf Heidenreich's team at Newcastle University, was published last month (October) in Cancer Cell (ii), which focussed on just one type of DNA mutation in AML to study a single pathway to cancer development.

The researchers found that a growth-promoting gene, called CCND2, was crucial for the survival of this type of cancer cell and, significantly, it was found that an already approved breast cancer drug called palbociclib designed to inhibit CCDN2 was able to block tumour development - therefore identifying it as a drug that could be used to target and treat AML.

Also in the same issue of Cancer Cell (iii) published in October the University of Birmingham team - this time in collaboration with scientists led by Professor Jan Jacob Schuringa at the University of Groningen in the Netherlands - published further research aimed at advancing tailored and targeted treatment for AML patients.

Of this research, Professor Bonifer explains: "Acute myeloid leukaemia is made up of several groups of cells with different combinations of mutations, some of which are so aggressive they allow these cancer cells to survive after treatment.

"Often these combinations of mutations are present before treatment, but we have never previously been able to identify them when a patient is first diagnosed with AML - meaning that the cancer can later return as a different disease which is often more aggressive.

"Our research in collaboration with the University of Groningen identified how to makes it possible to identify these cells when patients are first diagnosed with AML so that they can be treated with the right combination of drugs."
For more information please contact Emma McKinney, Communications Manager (Health Sciences), University of Birmingham, Email: or tel: +44-0-121-414-6681, or contact the press office on +44-0-7789-921-165 or

Notes to Editors:


University of Birmingham

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to